Introduction: Stomach cancer is the second in mortality and the fourth most frequent of all cancers in the world. In the recent decades, the number of patients with Signet ring cell carcinoma type has been growing. Unknown etiology with proven risk factors such as smoked and salted foods, smoking, metabolic syndrome, alcohol abuse and Helicobacter pylori infection. Five-year span survival is 20%-40%.
Case outline: Patient, 70 years old, in good health, came to the GP, because of pain she had been feeling in the lower back area for a couple of months. Sometimes she wakes up because of the pain below the chest. Belch, acid, lost three kilograms. Didn't pay any attention to the problem because earlier, due to severe osteoporosis, she had obtained a compression fracture of two vertebrae. Occult bleeding negative. Laboratory normal. Tenderness on palpation of epigastrium, the tumor mass is not palpable. Addressed immediate to esophagogastroduodenoscopy. Diagnosis: Ulcer ventriculi, region antrum. Histopathological findings: Gastric Adenocarcinoma, diffuse type, Signet ring cell. Computed tomography showed locoregional lymphadenopathy so responsible Consilium decided radical surgery and chemotherapy. Despite being treated, the patient pass away two years after the onset of the illness.
Conclusion: Primary health care workers have a big responsibility, because of nonspecific symptoms, in detection of gastric cancer. Good evaluation of patients who should be referred for esophagogastroduodenoscopy is essential. The doctor should keep in mind in the further course of treatment early postoperative complications, Dumping syndrome, appears ventral anastomosis, subocclusive disorders, gallbladders calculus formation, educate patients about nutrition, vitamins, monitor vitamin B12 and iron because patients are prone to vitamin deficiency and pernicious anemia. Psychological support for patients and their families is also very significant, through a concrete doctor-patient relationship.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Vol. 61, CA Cancer J Clin. p. 69–90.
2.
Kwon KJ, Shim KN, Song EM, Choi JY, Kim SE, Jung HK, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Vol. 17, Gastric Cancer. p. 43–53.
3.
Ma SH, Jung W, Weiderpass E, Jang J, Hwang Y, Ahn C, et al. Impact of alcohol drinking on gastric cancer development according to Helicobacter pylori infection status. Vol. 113, Br J Cancer. p. 1381–8.
4.
Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic significance of signet ring gastric cancer. Vol. 30, J Clin Oncol. p. 3493–8.
5.
Kranjčević K. Karcinom želuca u praksi liječnika obiteljske medicine. Vol. 69, Acta Med Croatica. p. 333–8.
6.
Lin Y, Ness-Jensen E, Hveem K, Lagergren J, Lu Y. Metabolic syndrome and esophageal and gastric cancer. Vol. 26, Cancer Causes Control. p. 1825–34.
7.
Lagergren J, Andersson G, Talback M, Drefahl S, Bihagen E, Härkönen J, et al. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site. Vol. 122, Cancer. p. 207–12.
8.
Lauwers GY, Carneiro F, Graham DY, Cuardo MP, Franceschi S, Montgomery E, et al. Gastric carcinoma. In: WHO Classification of Tumors of the Digestive System IARC Press.
9.
Post RS, IP V, F C, P G, D H, N H, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Vol. 52, J Med Genet. p. 361–74.
10.
Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. Vol. 1, JAMA Oncol. p. 23–32.
11.
Rubin GP, Saunders CL, Abel GA, McPhail S, Lyratzopoulos G, Neal RD. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. Vol. 112, Br J Cancer. p. 676–87.
12.
Chiu PW, Teoh AY, To KF, Wong SK, Liu SY, Lam CC, et al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Vol. 26, Surg Endosc. p. 3584–91.
13.
Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Vol. 21, Ann Surg Oncol. p. 1739–48.
14.
Tong J, Sun Z, Wang Z, Zhao YH, Huang BJ, Li K, et al. Early gastric cancer with signet-ring cell histologic type: risk factors of lymph node metastasis and indications of endoscopic surgery. Vol. 149, Surgery. p. 356–63.
15.
Sun W, Han X, Wu S, Yang C. Endoscopic Resection Versus Surgical Resection for Early Gastric Cancer: A Systematic Review and Meta-Analysis.
16.
Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Vol. 254, Ann Surg. p. 684–93.
17.
Maksimović Ž. Hirurgija– udžbenik za studente. Medicinski fakultet Univerziteta u Beogradu. Treće izmenjeno i dopunjeno izdanje.
18.
Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. Vol. 21, World J Gastroenterol. p. 11428–38.
19.
Andrić Z, Ranđelović T, Kovčin V, Gutović J, Crevar S, Murtezani Z, et al. Procena efikasnosti i toksičnosti protokola cisplatin, 5-fluorouracil i leukovorin u odnosu na protokol 5-fluorouracil, doksorubicin i mitomicin C u lečenju lokalno odmaklog i metastatskog karcinoma želuca. Vol. 140, Srp Arh Celok Lek. p. 305–12.
20.
Namikawa T, Munekage E, Munekage M, Maeda H, Yatabe T, Kitagawa H, et al. Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. Vol. 5, Mol Clin Oncol. p. 74–8.
21.
Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and upper gastrointestinal malignancies. Vol. 148, Gastroenterology. p. 1234–43.
22.
Nelson N. On Trial: Evidence From Using Aspirin to Prevent Cancer. Vol. 107, J Natl Cancer Inst.
23.
H WJE. pylori seems to reduce incidence of gastric cancer, review shows. Vol. 351, BMJ.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
